Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin®) eye drops against corneal neovascularization

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 247, Issue 10, 2009, Pages 1375-1382

  Koenig, Yanyan ^a   Bock, Felix ^a   Horn, Folkert ^a   Kruse, Friedrich ^a   Straub, Katja ^a   Cursiefen, Claus ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Angiogeneis; Bevacizumab; Cornea; Eye drops; Inhibition; Safety

Indexed keywords

BEVACIZUMAB; EYE DROPS; IMMUNOSUPPRESSIVE AGENT; STEROID;

ADULT; ARTICLE; CLINICAL ARTICLE; CORNEA DISEASE; CORNEA NEOVASCULARIZATION; CORNEA PERFORATION; CORNEA TRANSPLANTATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FLUORESCENCE ANGIOGRAPHY; HUMAN; KERATOPATHY; LIMBAL STEM CELL TRANSPLANTATION; LONG TERM CARE; MALE; MORPHOMETRICS; OFF LABEL DRUG USE; PRIORITY JOURNAL; RETINA BLOOD VESSEL; SHORT COURSE THERAPY; TREATMENT DURATION; VISUAL ACUITY;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; BLOOD VESSELS; CORNEA; CORNEAL DISEASES; CORNEAL NEOVASCULARIZATION; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY; EPITHELIUM, CORNEAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIMBUS CORNEAE; MALE; MIDDLE AGED; OPHTHALMIC SOLUTIONS; POSTOPERATIVE CARE; STEM CELL TRANSPLANTATION; TIME FACTORS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 69549112893     PISSN: 0721832X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00417-009-1099-1     Document Type: Article

References (22)

1. Chang JH, Gabison EE, Kato T, Azar DT (2001) Corneal neovascularization. Curr Opin Ophthalmol 12:242-249, doi: 10.1097/00055735-200108000-00002
2. Bock F, Koenig Y, Dietrich T, Zimmermann P, Baier M, Cursiefen C (2007) Inhibition of angiogenesis in the anterior chamber of the eye. Ophthalmologe 104:336-344, doi: 10.1007/s00347-007-1512-2
3. Cursiefen C, Chen L, Saint-Geniez M et al (2006) Nonvascular VEGF receptor 3 expression by corneal epithelium maintains avascularity and vision. Proc Natl Acad Sci U S A 103:11405-11410, doi: 10.1073/ pnas.0506112103
4. Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407:249-257, doi: 10.1038/35025220
5. Aiello LP, Avery RL, Arrigg PG et al (1994) Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331:1480-1487, doi: 10.1056/ NEJM199412013312203
6. Yoeruek E, Spitzer MS, Tatar O et al (2007) Safety profile of Bevacizumab on cultured human corneal cells. Cornea 26:977-982, doi: 10.1097/ICO.0b013e3180de1d0a
7. Bock F, Koenig Y, Kruse F, Baier M, Cursiefen C (2008) Bevacizumab (Avastin) eye drops inhibit corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 246:281-284, doi: 10.1007/s00417-007-0684-4
8. Kim SW, Ha BJ, Kim EK, Tchah H, Kim TI (2008) The effect of topical Bevacizumab on corneal neovascularization. Ophthalmology 115:e33-e38, doi: 10.1016/j.ophtha.2008.02.013
9. Philipp W, Speicher L, Humpel C (2000) Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas. Invest Ophthalmol Vis Sci 41:2514-2522
10. Cursiefen C, Rummelt C, Küchle M (2000) Immunohistochemical localization of vascular endothelial growth factor, transforming growth factor alpha, and transforming growth factor beta1 in human corneas with neovascularization. Cornea 19:526-533. doi: 10.1097/ 00003226-200007000-00025
11. Irigoyen JP, Moñoz-Cánoves P, Montero L et al (1999) The plasminogen activator system: Biology and regulation. Cell Mol Life Sci 56:104-132, doi: 10.1007/PL00000615
12. Blasi F (1999) Proteolysis, cell adhesion, chemotaxis, and invasiveness are regulated by the u-PA-u-PAR-PAI-1 system. Thromb Haemost 82:298-304
13. Bock F, Onderka J, Dietrich T et al (2007) Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. Invest Ophthalmol Vis Sci 48:2545-2552, doi: 10.1167/iovs.06-0570
14. Fernando NH, Hurwitz HI (2004) Targeted therapy of colorectal cancer: clinical experience with bevacizumab. Oncologist 9:11-18, doi: 10.1634/ theoncologist.9-suppl_1-11
15. Avery RL, Pieramici DJ, Rabena MD et al (2006) Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113:363-372, doi: 10.1016/j.ophtha.2005.11.019
16. Krum JM, Rosenstein JM (2004) New roles for VEGF in nervous tissue: beyond blood vessels. Exp Neurol 187:246-253, doi: 10.1016/ j.expneurol.2004.01.022
17. Soubrane G, Jerdan J, Karpouzas I et al (1990) Binding of basic fibroblast growth factor to normal and neovascularized rabbit cornea. Invest Ophthalmol Vis Sci 31:323-333
18. Bock F, Onderka J, Hos D, Horn F, Martus P, Cursiefen C (2008) Improved semiautomatic method for morphometry of angiogenesis and lymphangiogenesis in corneal flatmounts. Exp Eye Res 87:462-470, doi: 10.1016/j.exer.2008.08.007
19. Cursiefen C, Rummelt C, Küchle M, Schlötzer-Schrehardt U (2003) Pericyte recruitment in human corneal angiogenesis. Br J Ophthalmol 87:101-106, doi: 10.1136/bjo.87.1.101
20. Sadrai Z, Dastjerdi MH, Saban DR, Dana R (2008) Corneal penetration of topical bevacizumab (Avastin). ARVO poster, 2008.
21. Cursiefen C, Cao J, Chen L et al (2004) Inhibition of hemangiogenesis and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival. Invest Ophthalmol Vis Sci 45(8):2666-2673, doi: 10.1167/iovs.03-1380
22. Bachmann BO, Bock F, Wiegand SJ et al (2008) Promotion of graft survival by vascular endothelial growth factor a neutralization after high-risk corneal transplantation. Arch Ophthalmol 126(1):71-77, doi: 10.1001/ archopht.126.1.71